DrugId:  1
1. Name:  ADC4022
2. Groups:  Investigational
3. Description:  ADC4022 is an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  2
1. Name:  Lexaptepid Pegol
2. Groups:  Investigational
3. Description:  Lexaptepid Pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
4. Indication:  Not Available
DrugId:  3
1. Name:  ALKS 27
2. Groups:  Investigational
3. Description:  ALKS 27 is an inhaled formulation of trospium chloride for the treatment of chronic obstructive pulmonary disease (COPD). Study showed that ALKS 27 was well-tolerated over a wide dose range, with no dose-limited effects observed.
4. Indication:  Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).
DrugId:  4
1. Name:  BTA798
2. Groups:  Investigational
3. Description:  BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.
4. Indication:  Investigated for use/treatment in viral infection.
DrugId:  5
1. Name:  MLN-977
2. Groups:  Investigational
3. Description:  MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease. 
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  6
1. Name:  Ferric cation
2. Groups:  Approved
3. Description:  Ferric citrate (tetraferric tricitrate decahydrate) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
4. Indication:  For the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
DrugId:  7
1. Name:  Tabalumab
2. Groups:  Investigational
3. Description:  Tabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
4. Indication:  Not Available
DrugId:  8
1. Name:  Vonapanitase
2. Groups:  Investigational
3. Description:  Vonapanitase is under investigation for the treatment of Chronic Kidney Disease.
4. Indication:  Not Available
DrugId:  9
1. Name:  Iron isomaltoside 1000
2. Groups:  Approved, Investigational
3. Description:  Iron isomaltoside 1000 is under investigation in Iron Deficiency Anaemia. Iron isomaltoside 1000 has been investigated for the treatment and basic science of Anemia, Gastric Cancer, Esophageal Cancer, Chronic Kidney Disease, and Anemia, Iron-Deficiency, among others.
4. Indication:  Not Available
DrugId:  10
1. Name:  NCX 950
2. Groups:  Investigational
3. Description:  NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  11
1. Name:  CMLVAX100
2. Groups:  Investigational
3. Description:  CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.
4. Indication:  Investigated for use/treatment in leukemia (myeloid).
DrugId:  12
1. Name:  PDE4
2. Groups:  Investigational
3. Description:  Merck has developed a selective PDE4 inhibitor for the treatment of inflammatory diseases, such as asthma and chronic obstructive pulmonary disease. Whereas the potential therapeutic utility of PDE4 inhibition has been demonstrated in various preclinical animal models (e.g., in rheumatoid arthritis and multiple sclerosis), clinical evaluation has been restricted by dose-limiting side effects, mainly nausea and emesis.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  13
1. Name:  ABX-PTH
2. Groups:  Investigational
3. Description:  ABX-PTH is a fully human monoclonal antibody generated by Abgenix's technology platform. This drug targets and neutralizes the action of parathyroid hormone (PTH) for the treatment of a secondary hyperparathyroidism.
4. Indication:  Investigated for use/treatment in chronic renal failure and parathyroid disorders.
DrugId:  14
1. Name:  Actinium
2. Groups:  Investigational
3. Description:  Actinium has been investigated for the treatment of Breast Cancer and Pulmonary Disease, Chronic Obstructive.
4. Indication:  Not Available
DrugId:  15
1. Name:  GSK159797
2. Groups:  Investigational
3. Description:  GSK159797 ('797) is an inhaled, longer-acting Beta2 agonist developed for the treatment of respiratory disease such as asthma and COPD.
4. Indication:  Investigated for use/treatment in asthma and chronic obstructive pulmonary disease (COPD).
DrugId:  16
1. Name:  Alvelestat
2. Groups:  Investigational
3. Description:  Alvelestat has been investigated for the basic science of Chronic Obstructive Pulmonary Disease.
4. Indication:  Not Available
DrugId:  17
1. Name:  Gadolinium
2. Groups:  Approved, Investigational
3. Description:  Gadolinium is under investigation in Hypertension, ACUTE KIDNEY INJURY, and Chronic Kidney Disease. Gadolinium has been investigated for the basic science of CAD, Multiple Sclerosis, and Coronary Artery Disease.
4. Indication:  Not Available
DrugId:  18
1. Name:  DAS-431 IV
2. Groups:  Investigational
3. Description:  DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc. 
4. Indication:  Investigated for use/treatment in addictions, dementia, parkinson's disease, schizophrenia and schizoaffective disorders, and strokes.
DrugId:  19
1. Name:  Neramexane
2. Groups:  Investigational
3. Description:  Neramexane is a low-to-moderate affinity uncompetitive NMDA receptor antagonist.
4. Indication:  Investigated for use/treatment in alzheimer's disease, hearing loss, and pain (acute or chronic).
DrugId:  20
1. Name:  EVT-101
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in alzheimer's disease, neurologic disorders, pain (acute or chronic), and parkinson's disease.
DrugId:  21
1. Name:  Fluasterone
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in psoriasis and psoriatic disorders, hyperlipidemia, metabolic disease, cancer/tumors (unspecified), and obesity.
DrugId:  22
1. Name:  Tofimilast
2. Groups:  Investigational
3. Description:  Tofimilast has been used in trials studying the treatment of Asthma and Pulmonary Disease, Chronic Obstructive.
4. Indication:  Not Available
DrugId:  23
1. Name:  ATG002
2. Groups:  Investigational
3. Description:  ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.
4. Indication:  Investigated for use/treatment in diabetic foot ulcers and wounds.
DrugId:  24
1. Name:  XTL-6865
2. Groups:  Investigational
3. Description:  XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
4. Indication:  Investigated for use/treatment in hepatitis (viral, C).
DrugId:  25
1. Name:  Methoxy polyethylene glycol-epoetin beta
2. Groups:  Approved
3. Description:  Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
4. Indication:  For the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
